Bridging the Early-Stage Biotech Gap: Inside the Johnson & Johnson Partnering Ecosystem
At the Bio-Europe conference, leadership from Johnson & Johnson (J&J) provided an in-depth roadmap for navigating the pharmaceutical giant’s...
Moe Alsumidaie
The $1.3 Trillion Cannibal: Why 2026 is the Year of Big Pharma’s Great Buffet
The mid-sized oncology biotech firm was blindsided. After three years of aggressive expansion and a pipeline bolstered by the...
Why Most Drug Launch Strategies Fail Before Phase III
The leadership team thought they were ahead of their drug launch schedule. Phase II data were in. The mechanism...
From Insight to Impact: How Servier Is Rewriting KOL Engagement With Data
At an industry conference, we spoke with Yann Péoc’h, World Operations Transformation Excellence Director at Servier, about how deep...
Europe Has World-Class Biotech Science. This Is the Law Admitting Everything Else Is Broken.
The company had done everything right. Strong translational science. Clean Phase 2 data. Positive scientific advice from the EMA....
Compliance and Creativity Converge as MLR Reframes Modern Medical Content
In the ever-evolving landscape of the pharmaceutical and MedTech industries, balancing compliance with creativity is a crucial challenge. This...
Advancing Medical Operations with Deep KOL Intelligence and AI
At the 2025 Veeva Commercial Summit, we spoke with Eric Toron, Executive Director and Head of Operations at MSD...
How Daiichi Sankyo Europe Sees the Future of Medical Affairs in an AI-Driven Era
At Veeva Commercial Summit Europe, we spoke with Andreas Gerloff, Director of Medical Excellence Operations at Daiichi Sankyo Europe,...
How Medical Information Is Transforming Into a Strategic, Tech-Enabled Partner in Rare Disease Care
At the 2025 Veeva Commercial Summit Europe, we spoke with Michelle Bridenbaker, Corporate Medical Information Lead at Recordati and...
How Technology Is Rewiring Medical Affairs and the HCP Ecosystem
As the pharmaceutical industry faces an unprecedented surge of product launches, most companies plan to handle this expansion without...